BRPI0812311A2 - Uso de um peptídeo derivado da proteína e2, e6 e/ou e7 do hpv - Google Patents

Uso de um peptídeo derivado da proteína e2, e6 e/ou e7 do hpv

Info

Publication number
BRPI0812311A2
BRPI0812311A2 BRPI0812311-0A2A BRPI0812311A BRPI0812311A2 BR PI0812311 A2 BRPI0812311 A2 BR PI0812311A2 BR PI0812311 A BRPI0812311 A BR PI0812311A BR PI0812311 A2 BRPI0812311 A2 BR PI0812311A2
Authority
BR
Brazil
Prior art keywords
hpv
protein derived
derived peptide
peptide
protein
Prior art date
Application number
BRPI0812311-0A2A
Other languages
English (en)
Inventor
Sjoerd Henricus Van Der Burg
Gemma G Kenter
Cornelis Johannes Maria Malief
Original Assignee
Academish Ziekenhuis Liden H O D N Lumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academish Ziekenhuis Liden H O D N Lumc filed Critical Academish Ziekenhuis Liden H O D N Lumc
Publication of BRPI0812311A2 publication Critical patent/BRPI0812311A2/pt
Publication of BRPI0812311A8 publication Critical patent/BRPI0812311A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BRPI0812311A 2007-05-31 2008-05-27 uso de um peptídeo derivado da proteína e2, e6 e/ou e7 do hpv BRPI0812311A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Publications (2)

Publication Number Publication Date
BRPI0812311A2 true BRPI0812311A2 (pt) 2014-10-29
BRPI0812311A8 BRPI0812311A8 (pt) 2019-02-05

Family

ID=38477016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812311A BRPI0812311A8 (pt) 2007-05-31 2008-05-27 uso de um peptídeo derivado da proteína e2, e6 e/ou e7 do hpv

Country Status (10)

Country Link
US (2) US9562075B2 (pt)
EP (1) EP2155240B1 (pt)
JP (2) JP2010530362A (pt)
CN (1) CN101795705A (pt)
AU (1) AU2008269721B2 (pt)
BR (1) BRPI0812311A8 (pt)
CA (1) CA2688589A1 (pt)
ES (1) ES2482192T3 (pt)
MX (1) MX2009012922A (pt)
WO (1) WO2009002159A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2496916T3 (es) * 2007-05-31 2014-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
WO2017075571A1 (en) 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific cells from a naive t cell population
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
CN117018170A (zh) * 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
US11524063B2 (en) * 2017-11-15 2022-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
JP2021517895A (ja) * 2018-03-12 2021-07-29 スクイーズ バイオテクノロジーズ カンパニー Ｈｐｖ関連疾患を処置するための方法
TW202003019A (zh) * 2018-03-12 2020-01-16 美商Ｓｑｚ生物科技公司 細胞內投遞生物分子以修改免疫反應之方法
WO2019178057A1 (en) * 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Methods of treating cancer using burkholderia
MA52363A (fr) * 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
WO1997023237A1 (en) 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ES2249907T3 (es) 1998-05-23 2006-04-01 Leiden University Medical Center Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU2002219711B8 (en) * 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
JP2004535816A (ja) * 2001-07-20 2004-12-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
JP5106384B2 (ja) * 2005-04-27 2012-12-26 ライデン ユニバーシティ メディカル センター Ｈｐｖ誘導性上皮内腫瘍の治療方法及び治療手段
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
CN101795705A (zh) 2010-08-04
MX2009012922A (es) 2010-07-05
US9562075B2 (en) 2017-02-07
US20170143818A1 (en) 2017-05-25
BRPI0812311A8 (pt) 2019-02-05
WO2009002159A3 (en) 2009-02-12
CA2688589A1 (en) 2008-12-31
JP2010530362A (ja) 2010-09-09
EP2155240B1 (en) 2014-04-30
US20100196353A1 (en) 2010-08-05
JP5888823B2 (ja) 2016-03-22
WO2009002159A2 (en) 2008-12-31
AU2008269721A1 (en) 2008-12-31
AU2008269721B2 (en) 2013-01-10
ES2482192T3 (es) 2014-08-01
EP2155240A2 (en) 2010-02-24
JP2014185179A (ja) 2014-10-02

Similar Documents

Publication Publication Date Title
BRPI0812311A2 (pt) Uso de um peptídeo derivado da proteína e2, e6 e/ou e7 do hpv
DK2061886T3 (da) Små kationiske immunomodulerende peptider
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
BRPI0811637A2 (pt) Proteínas de fusão da imunoglobina
BRPI0820342A2 (pt) Modulação de tráfego de proteína
BRPI0909084A2 (pt) Composição líquida, e, composto de peptídeo.
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0822219A2 (pt) Ácidos nucléicos de aminotransferase e oxidoreductase e polipeptídeos e métodos de uso.
WO2011047087A3 (en) Protein detection via nanoreporters
DK1984517T3 (da) Fremgangsmåde til modulering af rekombinante proteiners mannoseindhold
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0919014A2 (pt) composição fixadora de cabelo, e, uso de uma composição
DK2046826T3 (da) Exendin-fusionsproteiner
BRPI0918027A2 (pt) enzimas de lise de peptidoglicano artificial e proteínas de ligação de peptidoglicano
BRPI0821995A2 (pt) Dispositivo de controle de fluido, e, anel de vedação
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0913216A2 (pt) uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
FR2925312B1 (fr) Utilisation cosmetique de proteines de type desmogleine i
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
EP2133342A4 (en) INHIBITOR OF PROTEINTHYROSINE PHOSPHATASE 1B, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]